Lucy Sharples

Lucy Sharples is an associate in Goodwin’s Technology and Life Sciences groups. She has experience in advising on a range of commercial and regulatory matters for life sciences companies, including licensing and collaboration agreements, manufacturing and services agreements, and clinical trial agreements. Lucy also advises on the intellectual property, commercial and regulatory aspects of venture capital investments, M&A transactions and IPOs, and provides regulatory advice on medicinal product and medical device issues.

Lucy has a background in medicine and healthcare, having studied medical sciences at the University of Cambridge.

Lucy’s recent experience includes:

• Advising Vicebio on its $100 million Series B financing led by by TCGX. Vicebio is focused on developing next-generation respiratory virus vaccines using the Molecular Clamp Technology
• Advising Forbion (via its new BioEconomy Fund) and FMC Ventures on their investment in the oversubscribed $14 million Series A funding round for SOLASTA Bio. Established in 2021, Glasgow-based SOLASTA Bio has developed the world's first technology platform for creating insect control agents that are nature-inspired rather than selected from a synthetic chemistry library
• Advised SynAffix and its selling shareholders on its sale to Lonza. Under the terms of the sale and purchase agreement, Lonza have paid Synaffix’s shareholders an upfront payment of €100 million, with the potential for shareholders to receive an additional payment of up to €60 million contingent on financial performance
• Advised Forbion Capital and Sofinnova Investments on its jointly led a $148 million series C investment round in Gyroscope Therapeutics Limited
• Advised Forbion Capital on the first tranche of its £20 million investment in Oxular Limited as part of Oxular’s £27 million Series A1 funding round
• Advised Vaccitech plc (Nasdaq: VACC) on its initial public offering of 6,500,000 American Depositary Shares representing 6,500,000 ordinary shares at an initial public offering price of $17 per ADS
• Advised COMPASS Pathways plc on its public follow-on offering of 4,000,000 American Depositary Shares representing 4,000,000 ordinary shares at a public offering price of $36 per share, for gross proceeds of approximately $144 million
• Advised MiNA Therapeutics Limited on its Research and Collaboration Agreement with Eli Lilly and Company

Prior to joining Goodwin, Lucy was an associate at Taylor Wessing LLP.